Asthma Treatment Market Size, Growth, Trends, Report 2022 to 2030

According to Report, the global asthma treatment market size was valued at USD 25.8 billion in 2021 and it is anticipated to rake USD 30.1 billion by 2030 with a CAGR of 2.6% from 2022 to 2030.

There has been a strong relation established between psychological disorders and its impact on asthma. The increasing occurrence of psychological disorders is expected to trigger asthma in patients, especially for those whose ailment in severely undertreated. This is expected to drive the global market growth. However, studies have found that there is a severe lack of adherence to asthma treatment, especially, in underdeveloped countries and an array of unmet needs. These factors are expected to hamper the market growth. Nonetheless, biologics for asthma management are expected to open new growth opportunities.

Get the sample copy of report@ https://www.novaoneadvisor.com/report/sample/6270

The global asthma treatment market is consolidated with the top 5 companies accounting for 75 percent of the total market share in 2020. The global market was dominated by GSK, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, and Teva. The corporations have been concentrating their efforts on product development and regulatory approval. In addition, the companies sell asthma medications as well as accessories such as inhalers.

Market Drivers

Increasing air pollution triggering asthma cases

Asthma is a chronic respiratory condition marked by fluctuating airflow restriction, bronchial hyper responsiveness, and inflammation of the airways. Air pollution appears to have a negative impact on asthma outcomes in both adults and children, according to research. Air pollution from traffic, nitrogen dioxide, and secondhand smoking (SHS) are all substantial risk factors for the development of asthma in children. Nonetheless, a link between air pollution and adult asthma development has yet to be demonstrated. Asthma symptoms, exacerbations, and decreased lung function can all be triggered by exposure to outside pollution.

For instance, in the US, Exposure to air pollution has long been associated with asthma, a serious and life-threatening chronic respiratory condition that impacts the quality of life of more than 23 million Americans. Asthma symptoms can be aggravated and asthma attacks might be triggered by air pollution. Children with asthma, which affects an estimated six million children in the United States, are particularly vulnerable to pollution.

Ask here for customization@ https://www.novaoneadvisor.com/report/customization/6270

Air pollution may impact DNA associated with asthma

A new study financed by the Environmental Protection Agency (EPA) sheds light on the link between air pollution and asthma. While experts aren’t sure why air pollution causes asthma, evidence suggests that it suppresses genes that control the immune system’s ability to distinguish between an allergen and a hazardous foreign substance like a virus or bacteria. The immune system then goes into overdrive, triggering an inflammatory reaction regardless of whether the drug is toxic, resulting in asthma.

Each of this asthma research has improved our understanding of childhood asthma and supplied crucial information to the Environmental Protection Agency (EPA) that may be used to protect human health and the environment.

Rising prevalence of psychological disorders to impact asthma in patients

Asthma has been recognized as a disorder in which psychological elements play a significant role since the turn of the twentieth century. Clinicians understand that emotional stress can trigger or exacerbate asthma and that a patient’s mental health can impair asthma control by influencing symptom presentation and treatment adherence. As a result, there is a bi-directional link between asthma and psychological issues.

Asthmatics have been associated with periods of heightened emotionality, and asthma exacerbations have been linked to periods of heightened emotionality. Depressive disorders are likely to be more common among people with asthma than in the general population, according to a variety of prevalence estimates, some of which reach 40%. Remarkably, there is a link between depression and asthma in both families and individuals; familial studies imply that the prevalence of one condition is higher in the family members of index cases with the other. Patients with bipolar affective disorders tend to have a higher chance of acquiring IgE-mediated allergy diseases, such as asthma than the general population. Anxiety disorders also have an elevated prevalence in asthma, affecting up to one-third of asthmatic children and adolescents, as well as 24% of asthmatic adults.

Unfortunately, ambiguous disease criteria, inconsistencies in nomenclature, limited samples, and an emphasis on outpatient or inpatient populations rather than the community complicate the research on the frequency of psychological and mental disorders in asthmatics. The World Mental Health Survey addresses some of these methodological issues by providing standardized data for 17 nations throughout the world.

Exposure to coarse particulate matter linked with asthma in children

Researchers theorized that this was because younger children spend more time outside than older children and their respiratory systems are still maturing. This is the first study to look at the long-term impact of coarse PM on asthma in a countrywide sample of children in the United States.

This conclusion is relevant because exposure to fine particulate matter (PM2.5) has been linked to the development of asthma and other respiratory and cardiovascular disorders in the past. Because the greater particle size restricts penetration deep into the lungs, coarse particulate matter was assumed to be less hazardous. Coarse PM, on the other hand, can settle in the lungs, and current evidence suggests that short-term exposure is linked to cardiovascular and respiratory problems.

Between 2009 and 2010, researchers looked at a dataset of approximately eight million children aged 5 to 20 who were enrolled in Medicaid in 34 states. They discovered that coarse PM exposure was linked to an increase in asthma diagnoses, hospitalizations, and emergency department visits, with children aged 11 and under is the most vulnerable to the negative health impacts of coarse PM exposure.

Market Opportunity

Biologics for asthma management to open new market opportunities

A biologic is a drug derived from the cells of a live organism, such as bacteria or mice, then tailored to target specific molecules in humans. Antibodies, inflammatory chemicals, and cell receptors are the targets for asthma. Biologics attempt to disrupt the processes that contribute to inflammation, which causes asthma symptoms, by targeting these molecules.

Patients who continue to experience symptoms despite taking normal daily controller drugs are given a biologic. Symptoms of poorly controlled asthma include recurrent hospital admissions, emergency room visits, or the need for oral steroids for exacerbations; waking up at night with difficulty breathing; requiring a fast-acting reliever medication, such as albuterol, several times a day or week; and requiring a fast-acting reliever medication, such as albuterol, several times a day or week. Before prescribing a biologic, clinicians should ensure that the patient is taking all of their other controller medications as prescribed, avoiding any potential triggers, and treating any other medical illnesses that may be exacerbating their asthma.

The main advantage of biologics has been a reduction in the number of asthma exacerbations, which includes ER visits, hospitalizations, and the need for oral steroids. Reduced asthma symptoms, lower dosages of other controller medications, and fewer missed school and work days are among the other advantages. Biologics have been found to improve asthmatic patients’ quality of life. Some biologics have been reported to help people with severe asthma improve their lung function.

Currently, five biologics for asthma are approved: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab, with numerous more in the works. Omalizumab is an antibody that targets IgE allergy antibodies. Mepolizumab, reslizumab, and benralizumab all target eosinophils, a type of cell that plays a role in allergic inflammation. Dupilumab is a monoclonal antibody that targets a receptor for two molecules that cause allergic inflammation. To determine which biologic might be best for treating asthma, a doctor will obtain screening tests such as blood work or environmental allergen skin prick testing. Except for reslizumab, omalizumab is approved for patients as young as six years old. All other biologics, except for reslizumab, are approved for individuals as young as twelve years old. Adults aged 18 and up are permitted to use Reslizumab.

Regional Analysis

The North America region is accounted the largest revenue share of over 44.3% in 2021. This segment was valued USD 15,852 million in 2021 and is expected to reach over USD 16,254 million by 2030 with a registered CAGR of 4.05 over the forecast period.

US

In 2021, 27.8 million Americans, or 10.7% of the population, had ever been diagnosed with asthma and reported that they still had asthma. Current asthma prevalence rates increased at a statistically significant average rate of 0.1 points per year from 2001 to 2010. Between 2010 and 2018, the average annual change was statistically insignificantly different and remained flat.

Asthma is linked to a variety of factors, including gender, race, ethnicity, and socioeconomic level, with males experiencing the condition at a higher rate than girls in childhood. In maturity, the trend reverses, with more women than males suffering from asthma. Race and ethnicity have a substantial impact on prevalence rates. When compared to any other racial or ethnic group in the United States, Puerto Ricans have the highest rate of asthma prevalence. In addition, black Americans are diagnosed with asthma at a higher rate than white Americans.

Canada

Asthma is a chronic lung illness that causes airflow restriction in the lungs, making breathing difficult for almost 3.8 million Canadians. It is Canada’s third most frequent chronic condition. Many environmental variables provoke asthma symptoms, which include shortness of breath, chest tightness, wheezing, and coughing, all of which narrows the airways (bronchial tubes). Every day, almost 300 Canadians are diagnosed with asthma, and around 250 Canadians die as a result of an asthma attack.

For good asthma management and symptom control, timely access to quality health care, treatment, and education is critical. Despite this, over half of respondents (44%) said their current drug coverage is insufficient, and 24% said they have avoided filling a prescription because they couldn’t afford it. Although family doctors, pediatricians, and emergency room doctors are more likely to diagnose asthma (63%) than asthma specialists (23%), the primary source of care and management for those living with asthma remains a family doctor or pediatrician (52%) followed by an asthma specialist (23%). Access issues, wait times to see a specialist, a lack of information and education on managing asthma, as well as referrals and follow-up following emergency care, are all top needs in our community. In a pandemic, this can be much more difficult and concerning, given the influence that heightened safety procedures, as well as the worry and dread associated with COVID-19, have on patients seeking treatment.

The poll also revealed that people’s perceptions of asthma control differ significantly from the clinical definition of control. Even during a worldwide pandemic, this can be a substantial impediment to optimizing asthma management. Although 83 percent of respondents believe their asthma is moderate to very well controlled (up from 63 percent during COVID-19), 59 percent report difficulty sleeping as a result of asthma symptoms, and 71 percent avoid exercise or physical activities as a result of asthma symptoms. Improved access to affordable drugs, reliable testing, and diagnosis, and early diagnosis and care can all help people with asthma live a better life.

Some of the prominent players in the Asthma Treatment Market include:

• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Roche Holding AG / Novartis AG
• Merck & Co., Inc.
• Koninklijke Philips N.V.
• Sanofi-Aventis SA
• MundiPharma.

Segments Covered in the Report

By Medication

• Quick-relief medication
• Long-term control medication

By Route of Administration

• Inhalers
• Prefilled syringes/vials
• Others

By Adjunct Therapy

• LAMA (long-acting muscarinic antagonists)
• LABA (long-acting beta antagonists)
• Others

By Distribution Channel

• Online pharmacies
• Hospital pharmacies
• Retail pharmacies & drug stores

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Click Here to View Full Report Table of Contents

Buy this Research Report@ https://www.novaoneadvisor.com/report/checkout/6270

You can place an order or ask any questions, please feel free to contact at sales@novaoneadvisor.com | +1 9197 992 333